Spero Therapeutics (SPRO) EBITDA Margin (2016 - 2026)
Spero Therapeutics posted quarterly EBITDA Margin of 2921.71% for Q1 2026, down 267092.0% year-on-year from N/an in Q1 2025, and down 583.7% on a QoQ basis from 427.34% in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of EBITDA Margin data on file, last reported at 2921.71% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 267092.0% year-over-year to 2921.71%; the trailing twelve-month figure through Mar 2026 stood at 107.71% (up 29247.0% YoY), and the FY2025 full-year result was 50.11%, up 20302.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 2921.71%, down from 427.34% in the prior quarter.
- Across five years, EBITDA Margin topped out at 159.59% in Q4 2022 and bottomed at 28604.62% in Q3 2024.
- The 5-year median for EBITDA Margin is 427.34% (2025), against an average of 2597.21%.
- The widest annual swing landed in 2024, when EBITDA Margin slumped 2713443 bps; it then jumped 2845915 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 159.59% in 2022, then slumped by 51 bps to 78.1% in 2023, then plunged by 207 bps to 83.93% in 2024, then plunged by 409 bps to 427.34% in 2025, then plunged by 584 bps to 2921.71% in 2026.
- The last three EBITDA Margin figures came in at 2921.71% (Q1 2026), 427.34% (Q4 2025), and 145.46% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.24% |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | -2,921.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,921.71% |
| Dec 31, 2025 | -427.34% |
| Sep 30, 2025 | -145.46% |
| Jun 30, 2025 | -17.22% |
| Mar 31, 2025 | -250.78% |
| Dec 31, 2024 | -83.93% |
| Sep 30, 2024 | -28,604.62% |
| Jun 30, 2024 | -322.90% |
| Mar 31, 2024 | -150.88% |
| Dec 31, 2023 | 78.10% |
| Sep 30, 2023 | -1,470.18% |
| Jun 30, 2023 | -438.66% |
| Mar 31, 2023 | -5,948.88% |
| Dec 31, 2022 | 159.59% |
| Sep 30, 2022 | -582.00% |
| Jun 30, 2022 | -1,438.84% |
| Mar 31, 2022 | -1,586.90% |
| Dec 31, 2021 | -189.35% |
| Sep 30, 2021 | 3,180.93% |
| Jun 30, 2021 | -881.81% |
| Mar 31, 2021 | -266.01% |
| Sep 30, 2020 | -49,868.42% |
| Jun 30, 2020 | -1,011.41% |
| Mar 31, 2020 | -1,369.37% |
| Dec 31, 2019 | -3,590.23% |
| Sep 30, 2019 | -381.33% |
| Jun 30, 2019 | -19,619.40% |
| Mar 31, 2019 | -65.34% |
| Dec 31, 2018 | -626.71% |
| Sep 30, 2018 | -1,591.34% |
| Jun 30, 2018 | -2,147.30% |
| Dec 31, 2017 | -1,396.58% |
| Sep 30, 2017 | -1,648.91% |
| Jun 30, 2017 | -3,920.88% |
| Mar 31, 2017 | -4,579.29% |
| Dec 31, 2016 | 13,553.85% |
| Sep 30, 2016 | -7,914.00% |